APSR2026-693

 
Late-Breaking
Submitted
Poster Presentation
 
AP06-040
P40
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1221123-46904-APSR AP06-040_439775.pdf
Format: PDF Only
01. Clinical Respiratory Medicine
15

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Ryutaro Tanaka * Fukushima Medical University Pulmonary Medicine Fukushima Japan
Yoshinori Tanino - Fukushima Medical University Pulmonary Medicine Fukushima Japan
Takefumi Nikaido - Fukushima Medical University Pulmonary Medicine Fukushima Japan
Yuki Sato - Fukushima Medical University Pulmonary Medicine Fukushima Japan
Natsumi Watanabe - Fukushima Medical University Pulmonary Medicine Fukushima Japan
Xintao Wang - Fukushima Medical University Pulmonary Medicine Fukushima Japan
Takahiro Kumanaka - Fukushima Medical University Pulmonary Medicine Fukushima Japan
Koshi Saito - Fukushima Medical University Pulmonary Medicine Fukushima Japan
Rina Harigane - Fukushima Medical University Pulmonary Medicine Fukushima Japan
Ryuki Yamada - Fukushima Medical University Pulmonary Medicine Fukushima Japan
Hikaru Tomita - Fukushima Medical University Pulmonary Medicine Fukushima Japan
Yasuhito Suzuki - Fukushima Medical University Pulmonary Medicine Fukushima Japan
Kenya Kanazawa - Fukushima Medical University Pulmonary Medicine Fukushima Japan
Ryuichi Togawa - Fukushima Medical University Pulmonary Medicine Fukushima Japan
Yoko Shibata - Fukushima Medical University Pulmonary Medicine Fukushima Japan
Presenting Author Details
Ryutaro
Tanaka
rtanaka@fmu.ac.jp
+819028889801
Under 30
Japan
Case Report
Treatment with avacopan for Granulomatosis with Polyangiitis with Pulmonary Involvement: a case report
Maximum 25 words
Abstract Content
 
 
 
 
Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) including granulomatosis with polyangiitis (GPA) is a rare life-threatening disorder affecting several organs, mainly the lungs and kidneys. Although glucocorticoids combined with rituximab or cyclophosphamide have been used to induce remission, the efficacy of avacopan, a selective C5a receptor antagonist, was recently shown in AAV, especially for rapidly progressive glomerulonephritis. However, its effectiveness for pulmonary involvement remains unclear.
A 67-year-old man was referred to our hospital because of fever, productive cough, and hematuria. His chest computed tomography showed bilateral ground-glass opacities and pleural effusion. Laboratory tests revealed renal dysfunction (Cr 5.48 mg/dL, eGFR 9 mL/min/1.73 m²) with elevated levels of myeloperoxidase antineutrophil cytoplasmic antibody (92.5 U/mL) and Krebs von den Lungen-6 (598 U/mL). Urinalysis demonstrated hematuria and proteinuria. In addition, nasal mucosal biopsy revealed granulomatous inflammation, leading to the diagnosis of GPA. High-dose methylprednisolone (1,000 mg/day for 3 days) was initiated, followed by oral prednisolone (40 mg/day) and intravenous cyclophosphamide (500 mg). Although his respiratory condition improved, renal function was deteriorated during steroid tapering. Therefore, avacopan (60 mg/day) was added to the treatment. After initiation of avacopan, renal function stabilized and pulmonary lesions were not deteriorated. He was discharged on day 50 without relapse.
C5a plays a critical role in neutrophil activation and vascular inflammation in AAV, and the efficacy of avacopan, the C5a receptor antagonist, has been demonstrated in clinical trials for AAV. However, the efficacy of avacopan for pulmonary involvement remains unclear because previous trials focused on renal outcomes. In this case, although avacopan was started after improvement of pulmonary involvement, avacopan possibly to contribute stabilizing both renal and pulmonary involvements during glucocorticoid tapering. This case demonstrated that avacopan may be a useful therapeutic option for GPA with pulmonary involvement in AAV.
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Avacopan, Granulomatosis with polyangiitis
maximum 3 keywords and no abbreviations, separated by commas
Authors declare no conflicts of interest.
301